Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Zoladex

Known as: ZDX 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2003
Highly Cited
2003
The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex… Expand
Highly Cited
1997
Highly Cited
1997
BACKGROUND We conducted a randomized, prospective trial comparing external irradiation with external irradiation plus goserelin… Expand
  • table 3
  • figure 1
  • figure 2
  • table 4
1996
1996
The objective of this study was to document previously unreported anemia in prostate cancer patients treated with neoadjuvant… Expand
Highly Cited
1991
Highly Cited
1991
Between November 1983 and February 1986, 358 patients with previously untreated metastatic prostatic carcinoma entered a… Expand
Highly Cited
1990
Highly Cited
1990
The hypothesis that adjuvant treatment designed to produce testicular atrophy would preserve fertility in males receiving cancer… Expand
Highly Cited
1989
Highly Cited
1989
Two multicenter, open, randomized phase III clinical trials were conducted in the United Kingdom to compare the effectiveness and… Expand
Highly Cited
1989
Highly Cited
1989
The endocrine and therapeutic effects of the LHRH agonist Zoladex have been assessed in 28 post-menopausal women with advanced… Expand
  • table I
  • figure 1
  • table II
Highly Cited
1989
Highly Cited
1989
One hundred thirty-four pre- and perimenopausal patients presenting with metastatic breast cancer (median age, 42 years; range… Expand
Highly Cited
1987
Highly Cited
1987
Thirteen premenopausal women with uterine fibroids were treated for a maximum of 6 months with a long-acting agonist of… Expand
Highly Cited
1986
Highly Cited
1986
Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone… Expand
  • figure 1
  • figure 2
  • figure 3